Treatment of experimental autoimmune myasthenia gravis with monoclonal antibodies to immune response gene products.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000917:Antibody Formation; D001402:B-Lymphocytes / Q000276:immunology; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D007518:Isoantibodies / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009157:Myasthenia Gravis / Q000628:therapy*; D011950:Receptors, Cholinergic / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D000911:Antibodies, Monoclonal; D000949:Histocompatibility Antigens Class II; D007518:Isoantibodies; D011950:Receptors, Cholinergic